Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dominik Sturm

Showing results (41-50 of 127) with videos related to

Pageof 13
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2010
TP53 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastomaElke Pfaff, Marc Remke, Dominik Sturm, et al.
Neuropathology : Official Journal of the Japanese Society of Neuropathology|July 18, 2015
Comparative integrated molecular analysis of intraocular medulloepitheliomas and central nervous system embryonal tumors with multilayered rosettes confirms that they are distinct nosologic entitiesAndrey Korshunov, Frederick A Jakobiec, Charles G Eberhart, et al.
European Journal of Cancer (Oxford, England : 1990)|December 21, 2022
Molecular diagnostics enables detection of actionable targets: the Pediatric Targeted Therapy 2.0 registryJonas Ecker, Florian Selt, Dominik Sturm, et al.
Acta Neuropathologica|October 21, 2015
Histologically distinct neuroepithelial tumors with histone 3 G34 mutation are molecularly similar and comprise a single nosologic entityAndrey Korshunov, David Capper, David Reuss, et al.
European Journal of Cancer (Oxford, England : 1990)|March 23, 2023
Corrigendum to 'Molecular diagnostics enables detection of actionable targets: the Pediatric Targeted Therapy 2.0 registry' [Eur J Cancer 180 (2023) 71-84]Jonas Ecker, Florian Selt, Dominik Sturm, et al.
European Journal of Cancer (Oxford, England : 1990)|February 6, 2017
Survival benefit for patients with diffuse intrinsic pontine glioma (DIPG) undergoing re-irradiation at first progression: A matched-cohort analysis on behalf of the SIOP-E-HGG/DIPG working groupGeert O Janssens, Lorenza Gandola, Stephanie Bolle, et al.
Acta Neuropathologica|July 7, 2019
Routine RNA sequencing of formalin-fixed paraffin-embedded specimens in neuropathology diagnostics identifies diagnostically and therapeutically relevant gene fusionsDamian Stichel, Daniel Schrimpf, Belén Casalini, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 14, 2011
FSTL5 is a marker of poor prognosis in non-WNT/non-SHH medulloblastomaMarc Remke, Thomas Hielscher, Andrey Korshunov, et al.
Acta Neuropathologica|October 25, 2013
Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous systemChristian Koelsche, Felix Sahm, David Capper, et al.
Neuro-Oncology Advances|November 25, 2024
Treatment-related survival patterns in diffuse intrinsic pontine glioma using a historical cohort: A report from the European Society for Pediatric Oncology DIPG/DMG RegistryJoshua N Baugh, Sophie Veldhuijzen van Zanten, Marta Fiocco, et al.
Pageof 13

Showing results (41-50 of 127) with videos related to

Sort By:
Pageof 13
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2010
TP53 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastomaElke Pfaff, Marc Remke, Dominik Sturm, et al.
Neuropathology : Official Journal of the Japanese Society of Neuropathology|July 18, 2015
Comparative integrated molecular analysis of intraocular medulloepitheliomas and central nervous system embryonal tumors with multilayered rosettes confirms that they are distinct nosologic entitiesAndrey Korshunov, Frederick A Jakobiec, Charles G Eberhart, et al.
European Journal of Cancer (Oxford, England : 1990)|December 21, 2022
Molecular diagnostics enables detection of actionable targets: the Pediatric Targeted Therapy 2.0 registryJonas Ecker, Florian Selt, Dominik Sturm, et al.
Acta Neuropathologica|October 21, 2015
Histologically distinct neuroepithelial tumors with histone 3 G34 mutation are molecularly similar and comprise a single nosologic entityAndrey Korshunov, David Capper, David Reuss, et al.
European Journal of Cancer (Oxford, England : 1990)|March 23, 2023
Corrigendum to 'Molecular diagnostics enables detection of actionable targets: the Pediatric Targeted Therapy 2.0 registry' [Eur J Cancer 180 (2023) 71-84]Jonas Ecker, Florian Selt, Dominik Sturm, et al.
European Journal of Cancer (Oxford, England : 1990)|February 6, 2017
Survival benefit for patients with diffuse intrinsic pontine glioma (DIPG) undergoing re-irradiation at first progression: A matched-cohort analysis on behalf of the SIOP-E-HGG/DIPG working groupGeert O Janssens, Lorenza Gandola, Stephanie Bolle, et al.
Acta Neuropathologica|July 7, 2019
Routine RNA sequencing of formalin-fixed paraffin-embedded specimens in neuropathology diagnostics identifies diagnostically and therapeutically relevant gene fusionsDamian Stichel, Daniel Schrimpf, Belén Casalini, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 14, 2011
FSTL5 is a marker of poor prognosis in non-WNT/non-SHH medulloblastomaMarc Remke, Thomas Hielscher, Andrey Korshunov, et al.
Acta Neuropathologica|October 25, 2013
Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous systemChristian Koelsche, Felix Sahm, David Capper, et al.
Neuro-Oncology Advances|November 25, 2024
Treatment-related survival patterns in diffuse intrinsic pontine glioma using a historical cohort: A report from the European Society for Pediatric Oncology DIPG/DMG RegistryJoshua N Baugh, Sophie Veldhuijzen van Zanten, Marta Fiocco, et al.
Pageof 13